Halibrell (Ranolazine)

Halibrell is indicated for the management of chronic stable angina and related chest pain conditions. It may be used as part of a comprehensive treatment plan that includes lifestyle modification and other antianginal drugs.

• Relief of angina pectoris symptoms in patients with documented chronic stable angina.
• Adjunct therapy when conventional antianginal agents are insufficient.
• Long‑term management to reduce frequency of angina attacks.
• Use in patients who cannot tolerate beta‑blockers or calcium channel blockers.
• Treatment of angina in patients with coexisting coronary artery disease.

Ranolazine can cause a range of side effects, most of which are mild to moderate in severity. Serious adverse reactions are less common but require medical attention.

Common

• Dizziness or light‑headed feeling, especially when standing quickly.
• Nausea, upset stomach, or mild gastrointestinal discomfort.
• Constipation or occasional diarrhea.
• Headache that may be intermittent or persistent.

Serious

• Prolonged QT interval leading to cardiac arrhythmias.
• Severe allergic reactions such as rash, itching, or swelling.
• Liver enzyme elevations indicating potential hepatic injury.

Before starting Halibrell, certain health considerations should be reviewed with a healthcare professional. These precautions help minimize risks and ensure safe use.

• Assess baseline cardiac rhythm and QT interval, especially in patients with known arrhythmias.
• Evaluate liver function tests prior to initiation and periodically during therapy.
• Use caution in patients with severe renal impairment; dose adjustment may be required.
• Discuss any history of hypersensitivity to ranolazine or related compounds.
• Avoid use during pregnancy or breastfeeding unless clearly indicated by a physician.
• Monitor for signs of hypotension when combined with other antianginal agents.

Ranolazine can interact with several medications, affecting its efficacy or safety profile. Awareness of these interactions helps prevent adverse outcomes.

Avoid

• Strong CYP3A inhibitors such as ketoconazole, clarithromycin, or itraconazole, which can increase ranolazine levels.
• Strong CYP2D6 inhibitors like quinidine or paroxetine, potentially leading to toxicity.
• Medications that significantly prolong the QT interval, for example, certain antiarrhythmics or antipsychotics.

Use with caution

• Other antianginal drugs (beta‑blockers, calcium channel blockers) that may enhance hypotensive effects.
• Digoxin, as ranolazine may raise digoxin concentrations.
• Anticoagulants such as warfarin, requiring closer monitoring of INR.
• Statins metabolized by CYP3A4 (e.g., simvastatin), which may have altered plasma levels.